Making Ivacaftor Easier for the Body to Absorb

A patent describing a specific way to turn a drug molecule into an amorphous solid to help the body absorb it more effectively.

What it covers

This patent describes how to create a solid dispersion of a drug molecule, specifically the compound known as Ivacaftor. In its natural state, this molecule is crystalline, which makes it hard for the human body to dissolve and absorb. By creating an amorphous solid dispersion—where the drug is mixed into a polymer matrix like HPMCAS—the molecules are locked in a disordered state that dissolves much faster in the gut. The patent specifically claims combinations of this drug with polymers and surfactants, often prepared through a process called spray drying.

What it doesn't cover

• —Does not cover the chemical structure of the drug molecule itself.
• —Does not cover crystalline forms of the drug.
• —Does not cover methods of treating specific diseases like cystic fibrosis.
• —Does not cover drug delivery methods that do not use solid dispersions.

The clever bit

The innovation lies in preventing the drug from reverting to its stable, poorly soluble crystalline form by trapping it within a polymer matrix, effectively 'freezing' it in a high-energy, easily dissolvable state.

Why it matters

This technology is essential for the commercial viability of Ivacaftor, a breakthrough treatment for cystic fibrosis. By solving the solubility problem, Vertex Pharmaceuticals enabled the drug to reach the bloodstream in therapeutic concentrations, forming the basis for the Kalydeco medication.

Real-world examples

• 1.Kalydeco (ivacaftor) tablets
• 2.Orkambi (lumacaftor/ivacaftor) tablets
• 3.Symdeko (tezacaftor/ivacaftor) tablets
• 4.Trikafta (elexacaftor/tezacaftor/ivacaftor) tablets